Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

NCT02688140 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT02688140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02688140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Lead sponsor
Technische Universität Dresden
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2016
Completion date
January 20, 2025
Enrollment
133 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukemia